evidencegaps
Primary study · included by 1 review

225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study).

Rosar 2025 · Rosar Florian, Khreish Fadi, Nagel Lea Sophie, et al. · Clinical nuclear medicine · 2025

Included by

Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.
Non-Cochrane · intervention · 2026 · cited as Rosar 2025 (REALITY, n=51) · Reference 30; Table 1; Figure 2A
Outcome this study informsPooled effectEvidenceCertainty
PSA decline of 50% or more (PSA50 response)
[225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)
Proportion (random-effects, REML) 0.47 [0.37, 0.56]8 studies · 323 participantsGRADE not reported
PSA decline of 50% or more (PSA50 response)
[225Ac]Ac-/[177Lu]Lu-PSMA combination (tandem) radioligand therapy vs None (single-arm studies)
Proportion (random-effects, REML) 0.44 [0.32, 0.56]6 studies · 169 participantsGRADE not reported

1 including review in total.